Recombinant FVIIa clinical trials
Also written activated recombinant human factor VII and NovoSeven.
How each study uses recombinant FVIIa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the recombinant FVIIa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Mar 1999 · Novoseven, Novoseven Rt · BLA 103665 (FDA, Purple Book)
- European Union
- 23 Feb 1996 · NovoSeven · EMEA/H/C/000074 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
57 studies that test it; most in 2005 (9)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 1 |
| 2001 | 8 |
| 2002 | 7 |
| 2004 | 5 |
| 2005 | 9 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 41 · Other 17
Novo Nordisk A/S (36) · Joseph Broderick, MD (2) · Laboratoire français de Fractionnement et de Biotechnologies (2) · rEVO Biologics (2) · Sheba Medical Center (2) · AryoGen Pharmed Co. (1) · Dr. David Gladstone (1) · University of Cincinnati (1)
Often tested with
Tested in the same studies.
Vatreptacog alfa (2) · Factor VIII (1) · Biosimilar Pharmaceuticals (1) · Warfarin (1) · Anti-inhibitor coagulant complex (1) · Prothrombin complex concentrate (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test recombinant FVIIa.
- Dec 2026Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)Phase 2 · Emory University
- Aug 2027A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaPhase 4 · Novo Nordisk A/S
Studies
Open first, then newest update. How each study uses recombinant FVIIa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 58
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2RecruitingPhase 3Joseph Broderick, MDNCT07227246Written as Recombinant Factor VIIa
- A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaRecruitingPhase 4Novo Nordisk A/SNCT07157423Written as Eptacog alfa (NovoSeven)
- SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsRecruitingPhase 4American Thrombosis and Hemostasis NetworkNCT04647227Written as coagulation factor VIIa [recombinant]-jncw
- Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)RecruitingPhase 2Emory UniversityNCT07136857Written as EPTACOG BETA
- Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major SurgeryTerminatedPhase 3Laboratoire français de Fractionnement et de BiotechnologiesNCT05695391Written as Coagulation Factor VIIa (Recombinant)
- Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke TrialActive, not recruitingPhase 3Joseph Broderick, MDNCT03496883Written as Recombinant Activated Factor VII (rFVIIa)
- Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedPhase 4Novo Nordisk A/SNCT01561391Written as activated recombinant human factor VII
- LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive ProceduresCompletedPhase 3Laboratoire français de Fractionnement et de BiotechnologiesNCT02548143Written as Coagulation Factor VIIa (Recombinant)
- Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII DeficiencyCompletedPhase 3AryoGen Pharmed Co.NCT03079063Written as Eptacog alfa, biosimilar
- "Spot Sign" Selection of Intracerebral Hemorrhage to Guide Hemostatic TherapyCompletedPhase 2Dr. David GladstoneNCT01359202Written as rfVIIa
- The Spot Sign for Predicting and Treating ICH Growth StudyCompletedPhase 2University of CincinnatiNCT00810888Written as recombinant activated factor VII
- Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With InhibitorsCompletedPhase 3rEVO BiologicsNCT02020369Written as Coagulation Factor VIIa (Recombinant)
- Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and InhibitorsCompletedPhase 3Novo Nordisk A/SNCT01392547Written as eptacog alfa (activated)
- Haemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsCompletedPhase 2Novo Nordisk A/SNCT00486278Written as eptacog alfa (activated)
- Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell TransplantationTerminatedPhase 2Novo Nordisk A/SNCT01564563Written as activated recombinant human factor VII
- Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedPhase 1Novo Nordisk A/SNCT01561417Written as activated recombinant human factor VII
- Recombinant Factor VIIa in Acute Intracerebral HaemorrhageCompletedPhase 2Novo Nordisk A/SNCT00426803Written as activated recombinant human factor VII
- Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture ReconstructionCompletedPhase 2Novo Nordisk A/SNCT01601457Written as activated recombinant human factor VII
- Use of NovoSeven® in Active Variceal BleedingCompletedPhase 2Novo Nordisk A/SNCT00154492Written as activated recombinant human factor VII
- Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver TransplantationCompletedPhase 2Novo Nordisk A/SNCT01563458Written as activated recombinant human factor VII
See all 58 studies that test recombinant FVIIa →
Given beside what is tested · 5 — recombinant FVIIa is usual care or a partner of the new treatment
- SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisWithdrawnPhase 3Emory UniversityNCT04563520Written as rFVIIa
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04543383Written as Recombinant Human Factor VIIa (rFVIIa)
- A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With InhibitorsCompletedPhase 2Novo Nordisk A/SNCT03196284Written as Eptacog alfa
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02622321Written as rFVIIa
- Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.Status unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04768699Written as TQG203/NovoSeven®
As the comparator · 3 — what is tested is compared with recombinant FVIIa
- Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With InhibitorsCompletedPhase 3AryoGen Pharmed Co.NCT03935334Written as Eptacog alfa, activated (Novoseven)
- Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With InhibitorsTerminatedPhase 2/3CSL BehringNCT02484638Written as Eptacog alfa (activated)
- A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150CompletedPhase 2/3BayerNCT01625390Written as eptacog alfa [activated]
Codes
What other systems call recombinant FVIIa · ClinicalTrials.gg INT003954
- MeSH (NLM) C103587recombinant FVIIaOne source NLM
- UNII (FDA) AC71R787OVCOAGULATION FACTOR VIIA RECOMBINANT HUMANConfirmed FDA, NLM
- RxNorm 253149One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C103587 | recombinant FVIIa | One source NLM |
| UNII (FDA) | AC71R787OV | COAGULATION FACTOR VIIA RECOMBINANT HUMAN | Confirmed FDA, NLM |
| RxNorm | 253149 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.